# Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Source: https://onco.cc/trials/nct03257033/  
OnCo record `nct03257033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by RenovoRx, now recruiting.

## Summary

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC is a phase 3 interventional study registered as NCT03257033 by RenovoRx, with 190 participants planned, started 2018-03-12 and due to reach its primary completion in 2027-06. Interventions recorded: Gemcitabine, nab-paclitaxel and RenovoCath.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03257033
- Phase: 3
- Setting: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
- Sponsor: RenovoRx
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT03257033: https://clinicaltrials.gov/study/NCT03257033

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct03257033.json